Indian Pharmaceutical Industry: A New Milestone

India has long been recognized as the world's pharmacy, primarily due to its prowess in producing generic medicines and vaccines. The success story began with the 1970 patent regime, allowing Indian companies to manufacture medicines discovered elsewhere using alternative production processes. This model improved access to affordable medicines and positioned India as the largest supplier of generic drugs globally. However, it also resulted in fewer ventures into new drug discovery, a risky and expensive endeavor.

Wockhardt's Breakthrough: ZAYNICH™

• On May 30, 2026, the US FDA approved ZAYNICH™ (cefepime and zidebactam), a new intravenous antibiotic.
• It targets complicated urinary tract infections caused by Gram-negative bacteria with distinctive outer cell walls, making them difficult to kill.
• This achievement is notable as it marks the first new chemical entity fully discovered, developed, and commercialized by an Indian pharmaceutical company to receive US FDA approval.

The development comes at a crucial time when antimicrobial resistance is a rising global health threat. Many large pharmaceutical companies have reduced or stopped antibiotic research due to poor commercial returns.

Drug Development and Approval

• ZAYNICH™ underwent a Phase III trial with 530 patients across multiple countries.
• It received approval from the Drugs Controller General of India (DCGI) on May 27, 2026.
• Marketing authorization applications have been submitted in Europe.

Significance of the Approval

• Dr. Habil F. Khorakiwala highlighted the challenge of antimicrobial resistance and the potential impact of ZAYNICH™ on treatment options for severe Gram-negative infections.
• Complicated UTIs represent a subset of multidrug-resistant Gram-negative infections, and ZAYNICH™ offers a safer, more effective treatment.

Global and Indian Burden

• Globally, Gram-negative bacteria cause about 60% of infections, with rising resistance.
• In India, the burden of UTIs is roughly three million cases annually, with 1.2 to 1.3 million hospital-treated cases.
• India faces faster resistance development due to hygiene, sanitation, and antibiotic misuse.

Treatment and Availability

• ZAYNICH™ is intended for hospital use as it requires intravenous administration.
• Treatment lasts 7-10 days, with a projected cost of $12,000 to $15,000 in the US and 75-80% lower in India.

Compassionate Use and Survival Rates

• More than 80 patients were treated under compassionate use, with a survival rate of over 90%.

Innovation and Future Prospects

• ZAYNICH™ belongs to a new class of antibiotics, a beta-lactam enhancer, acting on a unique bacterial mechanism.
• The development involved a complex manufacturing process in India.

This milestone underscores India's potential in drug discovery and the global fight against antimicrobial resistance.